Dare Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 0.00 shares.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 0.00 shares.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 0.00 shares.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-03-31 was 0.00 shares.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 370.23K shares, a 790.70% increase from fiscal 2014.
- Dare Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2014 was 41.57K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-14 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-12 | |
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | 370.23K shares 10-K · filed 2016-03-10 |
| 2015-09-30 | 46.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | 370.51K shares derived: sum of 4 quarters · filed 2015-11-16 |
| 2015-06-30 | 16.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | 325.59K shares derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | 307.48K shares 10-Q · filed 2015-05-06 | 341.01K shares derived: sum of 4 quarters · filed 2015-05-06 |
| 2014-12-31 | 285.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | 41.57K shares 10-K · filed 2015-03-19 |
| 2014-09-30 | 1.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | |
| 2014-06-30 | 31.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | |
| 2014-03-31 | 8.03K shares 10-Q · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |